Levetiracetam (extended-release)

Routes
Oral (PO)
Half-Life (t½)
PO: 7h
Formula
C8H14N2O2
Molecular Weight
170.21 g/mol
PubChem CID
5284583
Aliases
Keppra XR

Pharmacological Mechanism

Extended-release formulation of levetiracetam — same SV2A binding mechanism, once-daily dosing improves adherence. Same pharmacology as IR levetiracetam.

Half-Life & Elimination Curve (PO: 7h)

100%50%25%12.5%0%0h0×t½7h1×t½14h2×t½21h3×t½28h4×t½35h5×t½0×t½ (0h): 100% remaining (~15.2 mg/L)1×t½ (7h): 50% remaining (~7.62 mg/L)2×t½ (14h): 25% remaining (~3.81 mg/L)3×t½ (21h): 12.5% remaining (~1.91 mg/L)4×t½ (28h): 6.3% remaining (~0.953 mg/L)5×t½ (35h): 3.1% remaining (~0.476 mg/L)
Plasma (PO)t½ Decay (7h)
  • 0×t½0h100% (15.2 mg/L)
  • 1×t½7h50% (7.62 mg/L)
  • 2×t½14h25% (3.81 mg/L)
  • 3×t½21h12.5% (1.91 mg/L)
  • 4×t½28h6.3% (0.953 mg/L)
  • 5×t½35h3.1% (0.476 mg/L)
Elimination t½7h (PO)
Rate Constant (ke)0.099 h⁻¹
Time to Peak (Tmax)5.52h
Est. Peak (Cmax)15.2 mg/L
Clearance (CL)3.76 L/h
97% Washout (5×t½)35h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References